Transretinale Biopsie beim intraokularen Lymphom

Metz, C.; Schueler, A.; Metz, K.; Gök, Mehmet Ali; Bornfeld, Norbert

doi:10.1055/s-0041-102900

Cited by 8 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the series reported in the literature, TRB provided sufficient material for pathological examination in 88.9% to 100% of cases. 22,23,24,25,26,27,28,29 Choroidal melanoma was detected in 50-100% of cases in cyto/histopathological examination of TRB material. 22,23,24,25,26,27,28,30,31,32 Therefore, TRB is mostly performed for the diagnosis of uveal melanoma.…”

Section: Transretinal Biopsy With Pars Plana Vitrectomymentioning

confidence: 99%

See 1 more Smart Citation

Surgical Approach in Intraocular Tumors

Gündüz¹,

Mirzayev²

2022

tjo

View full text Add to dashboard Cite

Surgery in intraocular tumors is done for excision/biopsy and the management of complications secondary to the treatment of these tumors. Excision/biopsy of intraocular tumors can be done via fine-needle aspiration biopsy (FNAB), transretinal biopsy (TRB), partial lamellar sclerouvectomy (PLSU), and endoresection. FNAB, TRB, and PLSU can be used in tumors that cannot be diagnosed by clinical examination and other ancillary testing methods. PLSU is employed in tumors involving the iridociliary region and choroid anterior to the equator. Excisional PLSU is performed for iridociliary and ciliary body tumors with less than 3 clock hours of iris and ciliary body involvement and choroidal tumors with a base diameter less than 15 mm. However, for biopsy, PLSU can be employed with any size tumor. Endoresection is a procedure whereby the intraocular tumor is excised using vitrectomy techniques. The rationale for performing endoresection is based on the fact that irradiated uveal melanomas may cause complications such as exudation, neovascular glaucoma, and intraocular pigment and tumor dissemination (toxic tumor syndrome), and removing the dead tumor tissue may contribute to better visual outcome. Endoresection is recommended 1-2 weeks after external radiotherapy. Pars plana vitrectomy is also used in the management of complications including vitreous hemorrhage, retinal detachment, and epiretinal membrane that can occur after treatment of posterior segment tumors using radiotherapy and transpupillary thermotherapy. It is important to make sure the intraocular tumor has been eradicated before embarking on such treatment.

show abstract

Section: Transretinal Biopsy With Pars Plana Vitrectomymentioning

confidence: 99%

“…Histo 22,2,24,25,28,29 222 164 (73.9) 14 (6.3) 10 (4.5) 2 (0.9) 1 (0.5) 1 (0.5) 3 (1.4) 2 (0.9) 1 (0.5) unpigmented ciliary epithelium, as this will result in vitreous loss. If vitreous loss occurs, vitrectomy should be performed at the wound edges with an ocutome.…”

Section: Surgical Indication and Techniquementioning

confidence: 99%

Surgical Approach in Intraocular Tumors

Gündüz¹,

Mirzayev²

2022

tjo

View full text Add to dashboard Cite

show abstract

“…2 Early diagnosis of vitreoretinal lymphoma (VRL) is vital, but remains a challenge as vitreous biopsy can be repeatedly non-informative in some cases. 3,4 Ophthalmological examination for diagnosis has been found to have high positive and negative predictive values, 3 although the fact that VRLs can mimic uveitic processes has to be taken into account.…”

Section: Introductionmentioning

confidence: 99%

Use of intravitreal rituximab and methotrexate in vitreoretinal lymphoma

Rahhal-Ortuño

Udaondo

Fernández-Santodomingo

et al. 2020

European Journal of Ophthalmology

View full text Add to dashboard Cite

A 64-year-old Caucasian woman was referred to our hospital after referring vision loss; she had been previously diagnosed with systemic diffuse large B-cell lymphoma. Retinal and optic nerve involvement were found in her right eye, and iris and vitreous involvement were found in her left eye. Vitreoretinal lymphomas (VRL) are rare in medical literature, hence there is a lack of standardised studies regarding therapeutic options in these patients. In our patient, we decided to add intravitreal injections of rituximab and methotrexate to systemic chemotherapy, and to perform pars plana vitrectomy.

show abstract